FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244212929> ?p ?o ?g. }

• W4244212929 abstract "Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly starts in autumn or winter and remits in spring. The prevalence of SAD depends on latitude and ranges from 1.5% to 9%. The predictable seasonal aspect of SAD provides a promising opportunity for prevention in people who have a history of SAD. This is one of four reviews on the efficacy and safety of interventions to prevent SAD; we focus on agomelatine and melatonin as preventive interventions.To assess the efficacy and safety of agomelatine and melatonin (in comparison with each other, placebo, second-generation antidepressants, light therapy, psychological therapy or lifestyle interventions) in preventing SAD and improving person-centred outcomes among adults with a history of SAD.We searched Ovid MEDLINE (1950- ), Embase (1974- ), PsycINFO (1967- ) and the Cochrane Central Register of Controlled Trials (CENTRAL) to 19 June 2018. An earlier search of these databases was conducted via the Cochrane Common Mental Disorders Controlled Trial Register (CCMD-CTR) (all years to 11 August 2015). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature, Web of Science, the Cochrane Library, the Allied and Complementary Medicine Database and international trial registers (to 19 June 2018). We also conducted a grey literature search and handsearched the reference lists of included studies and pertinent review articles.To examine efficacy, we included randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. For adverse events, we intended also to include non-randomised studies. We planned to include studies that compared agomelatine versus melatonin, or agomelatine or melatonin versus placebo, any second-generation antidepressant, light therapy, psychological therapies or lifestyle changes. We also intended to compare melatonin or agomelatine in combination with any of the comparator interventions mentioned above versus the same comparator intervention as monotherapy.Two review authors screened abstracts and full-text publications, abstracted data and assessed risk of bias of included studies independently. We intended to pool data in a meta-analysis using a random-effects model, but included only one study.We identified 3745 citations through electronic searches and reviews of reference lists after deduplication of search results. We excluded 3619 records during title and abstract review and assessed 126 full-text papers for inclusion in the review. Only one study, providing data of 225 participants, met our eligibility criteria and compared agomelatine (25 mg/day) with placebo. We rated it as having high risk of attrition bias because nearly half of the participants left the study before completion. We rated the certainty of the evidence as very low for all outcomes, because of high risk of bias, indirectness, and imprecision.The main analysis based on data of 199 participants rendered an indeterminate result with wide confidence intervals (CIs) that may encompass both a relevant reduction as well as a relevant increase of SAD incidence by agomelatine (risk ratio (RR) 0.83, 95% CI 0.51 to 1.34; 199 participants; very low-certainty evidence). Also the severity of SAD may be similar in both groups at the end of the study with a mean SIGH-SAD (Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders) score of 8.3 (standard deviation (SD) 9.4) in the agomelatine group and 10.1 (SD 10.6) in the placebo group (mean difference (MD) -1.80, 95% CI -4.58 to 0.98; 199 participants; very low-certainty evidence). The incidence of adverse events and serious adverse events may be similar in both groups. In the agomelatine group, 64 out of 112 participants experienced at least one adverse event, while 61 out of 113 did in the placebo group (RR 1.06, 95% CI 0.84 to 1.34; 225 participants; very low-certainty evidence). Three out of 112 patients experienced serious adverse events in the agomelatine group, compared to 4 out of 113 in the placebo group (RR 0.76, 95% CI 0.17 to 3.30; 225 participants; very low-certainty evidence).No data on quality of life or interpersonal functioning were reported. We did not identify any studies on melatonin.Given the uncertain evidence on agomelatine and the absence of studies on melatonin, no conclusion about efficacy and safety of agomelatine and melatonin for prevention of SAD can currently be drawn. The decision for or against initiating preventive treatment of SAD and the treatment selected should consider patient preferences and reflect on the evidence base of all available treatment options." @default.
• W4244212929 created "2022-05-12" @default.
• W4244212929 creator A5013031059 @default.
• W4244212929 creator A5017069277 @default.
• W4244212929 creator A5018268103 @default.
• W4244212929 creator A5031031174 @default.
• W4244212929 creator A5045563662 @default.
• W4244212929 creator A5055744760 @default.
• W4244212929 creator A5068948548 @default.
• W4244212929 creator A5070892743 @default.
• W4244212929 creator A5073935870 @default.
• W4244212929 creator A5075837274 @default.
• W4244212929 creator A5085036522 @default.
• W4244212929 date "2019-06-17" @default.
• W4244212929 modified "2023-10-18" @default.
• W4244212929 title "Melatonin and agomelatine for preventing seasonal affective disorder" @default.
• W4244212929 cites W1496028880 @default.
• W4244212929 cites W1514970763 @default.
• W4244212929 cites W1915316839 @default.
• W4244212929 cites W1951707104 @default.
• W4244212929 cites W1964435302 @default.
• W4244212929 cites W1971570253 @default.
• W4244212929 cites W1975732958 @default.
• W4244212929 cites W1975896776 @default.
• W4244212929 cites W2006546769 @default.
• W4244212929 cites W2021804141 @default.
• W4244212929 cites W2026774904 @default.
• W4244212929 cites W2037264357 @default.
• W4244212929 cites W2037377025 @default.
• W4244212929 cites W2045854014 @default.
• W4244212929 cites W2052771854 @default.
• W4244212929 cites W2055145238 @default.
• W4244212929 cites W2059735897 @default.
• W4244212929 cites W2060301684 @default.
• W4244212929 cites W2064447107 @default.
• W4244212929 cites W2069045860 @default.
• W4244212929 cites W2086187065 @default.
• W4244212929 cites W2086546977 @default.
• W4244212929 cites W2089248332 @default.
• W4244212929 cites W2104675861 @default.
• W4244212929 cites W2107278158 @default.
• W4244212929 cites W2108025393 @default.
• W4244212929 cites W2114613490 @default.
• W4244212929 cites W2123058458 @default.
• W4244212929 cites W2126096066 @default.
• W4244212929 cites W2130122107 @default.
• W4244212929 cites W2135726950 @default.
• W4244212929 cites W2140140017 @default.
• W4244212929 cites W2145609303 @default.
• W4244212929 cites W2156098321 @default.
• W4244212929 cites W2157823046 @default.
• W4244212929 cites W2161279269 @default.
• W4244212929 cites W2161297280 @default.
• W4244212929 cites W246286872 @default.
• W4244212929 cites W2588681363 @default.
• W4244212929 cites W2735583099 @default.
• W4244212929 cites W2902265153 @default.
• W4244212929 cites W2916841405 @default.
• W4244212929 cites W3022473347 @default.
• W4244212929 cites W40416711 @default.
• W4244212929 cites W4231809474 @default.
• W4244212929 cites W4239136709 @default.
• W4244212929 cites W4242879601 @default.
• W4244212929 cites W4244911878 @default.
• W4244212929 cites W4247665917 @default.
• W4244212929 cites W4253643104 @default.
• W4244212929 cites W4292806894 @default.
• W4244212929 cites W4294215472 @default.
• W4244212929 cites W8245721 @default.
• W4244212929 doi "https://doi.org/10.1002/14651858.cd011271.pub3" @default.
• W4244212929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31206585" @default.
• W4244212929 hasPublicationYear "2019" @default.
• W4244212929 type Work @default.
• W4244212929 citedByCount "7" @default.
• W4244212929 countsByYear W42442129292020 @default.
• W4244212929 countsByYear W42442129292021 @default.
• W4244212929 countsByYear W42442129292022 @default.
• W4244212929 countsByYear W42442129292023 @default.
• W4244212929 crossrefType "journal-article" @default.
• W4244212929 hasAuthorship W4244212929A5013031059 @default.
• W4244212929 hasAuthorship W4244212929A5017069277 @default.
• W4244212929 hasAuthorship W4244212929A5018268103 @default.
• W4244212929 hasAuthorship W4244212929A5031031174 @default.
• W4244212929 hasAuthorship W4244212929A5045563662 @default.
• W4244212929 hasAuthorship W4244212929A5055744760 @default.
• W4244212929 hasAuthorship W4244212929A5068948548 @default.
• W4244212929 hasAuthorship W4244212929A5070892743 @default.
• W4244212929 hasAuthorship W4244212929A5073935870 @default.
• W4244212929 hasAuthorship W4244212929A5075837274 @default.
• W4244212929 hasAuthorship W4244212929A5085036522 @default.
• W4244212929 hasBestOaLocation W42442129292 @default.
• W4244212929 hasConcept C118552586 @default.
• W4244212929 hasConcept C126322002 @default.
• W4244212929 hasConcept C142724271 @default.
• W4244212929 hasConcept C168563851 @default.
• W4244212929 hasConcept C17744445 @default.
• W4244212929 hasConcept C197934379 @default.
• W4244212929 hasConcept C199539241 @default.
• W4244212929 hasConcept C204787440 @default.
• W4244212929 hasConcept C27081682 @default.

• next